TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. - Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. - Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis.  Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. TiGenix is based in Leuven, Belgium, and has operations in Madrid, Spain.
Show more
Type
Subsidiary
Parent Company
Takeda Pharmaceutical
HQ
Leuven, BE
Founded
2000
TiGenix was founded in 2000 and is headquartered in Leuven, BE
Report incorrect company information

Key People/Management at TiGenix

Eduardo Bravo

Eduardo Bravo

Managing Director and Chief Executive Officer
Claudia D’Augusta

Claudia D’Augusta

Chief Financial Officer
Marie Richard

Marie Richard

Chief Medical Officer
Susana Rojo

Susana Rojo

Director of Human Resources
Maria Pascual

Maria Pascual

Vice President, Regulatory Affairs and Corporate Quality
Wilfried Dalemans

Wilfried Dalemans

Chief Technical Officer
Show more

TiGenix Office Locations

TiGenix has an office in Leuven
Leuven, BE (HQ)
12 Romeinse straat
Show all (1)
Report incorrect company information

TiGenix Financials and Metrics

Summary Metrics

Founding Date

2000

Total Funding

$37.5 m

Investors

TiGenix is a subsidiary of Takeda Pharmaceutical
Report incorrect company information

TiGenix News and Updates

Takeda to add plant, 70 jobs in Ireland as it builds on deal for TiGenex

Takeda, which recently announced a $627 million deal to buy biotech TiGenix, is upping its bet on its stem cell therapy investment, with a new plant and 70 jobs at its manufacturing site in Ireland.

Bone Grafts And Substitutes Market Expand Their Businesses With New Investments by 2025

Bone grafts and substitutes (BGS) comprise the products that are used for the replacement of missing bones or to repair bone fractures. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information